U.S. Markets open in 1 hr 3 mins

Eledon Pharmaceuticals, Inc. (ELDN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.000.00 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.00
Open6.94
Bid7.65 x 4000
Ask8.15 x 800
Day's Range6.42 - 7.09
52 Week Range5.91 - 27.32
Volume134,199
Avg. Volume68,304
Market Cap100.146M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Eledon Pharmaceuticals to Present at Two Investor Conferences in September

    IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview and participate in one-on-one investor meetings at the HC Wainwright 23rd Annual Global Investment Con

  • GlobeNewswire

    Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results

    Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022 Reached agreement with the FDA to conduct a preclinical renal transplant study evaluating AT-1501 monotherapy in four non-human primates; launched academic collaboration to conduct the study with data expected mid-2022 Announces plans to develop AT-1501 as a therapy for IgA nephropathy (IgAN), the fourth potential indicatio

  • GlobeNewswire

    Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021

    Management to host conference call and webcast at 4:30 pm ETIRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that it plans to release financial results for the second quarter ended June 30, 202